Great Lakes Advisors LLC Takes Position in Lantheus Holdings, Inc. $LNTH

Great Lakes Advisors LLC acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 36,680 shares of the medical equipment provider’s stock, valued at approximately $4,069,000. Great Lakes Advisors LLC owned approximately 0.06% of Lantheus as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. Western Wealth Management LLC acquired a new position in shares of Lantheus in the first quarter worth $25,000. Smartleaf Asset Management LLC increased its holdings in Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares during the period. Parallel Advisors LLC increased its holdings in Lantheus by 122.6% during the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 298 shares during the period. Osterweis Capital Management Inc. acquired a new stake in Lantheus in the 2nd quarter valued at about $36,000. Finally, Bessemer Group Inc. raised its position in Lantheus by 221.2% in the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 354 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Trading Down 0.2%

LNTH opened at $100.24 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06. Lantheus Holdings, Inc. has a one year low of $49.67 and a one year high of $111.86. The company has a market cap of $6.54 billion, a P/E ratio of 24.21 and a beta of -0.03. The business’s 50-day simple moving average is $104.17 and its 200-day simple moving average is $90.28.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The company had revenue of $388.18 million for the quarter, compared to analysts’ expectations of $363.23 million. During the same quarter last year, the company earned $1.57 earnings per share. The firm’s revenue for the quarter was up 2.7% on a year-over-year basis. As a group, equities research analysts expect that Lantheus Holdings, Inc. will post 4.54 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on LNTH shares. TD Cowen downgraded Lantheus from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $110.00 to $102.50 in a research report on Monday, August 3rd. Leerink Partners set a $102.50 price target on shares of Lantheus in a research note on Monday, August 3rd. Brookline Capital Markets cut shares of Lantheus from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Citigroup reissued an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. Finally, Wall Street Zen lowered shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Four analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, Lantheus currently has an average rating of “Hold” and a consensus price target of $108.11.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.